40. Thor J, Lundberg J, Ask J, et al. Application of statistical process control in healthcare improvement: systematic review. Qual Saf Health Care 2007; 16(5): 387-399. 41. Ganley H. Demonstration of analysis and reporting for the NSW Therapeutic Advisory Group. Bounty Brokers Pty Ltd, 2012. 42. Lane S, Weeks A, Scholefield H, et al. Monitoring obstetricians’ performance with statistical process control charts. BJOG 2007; 114(5): 614-618. 43. R. The Science of Improvement on a Whiteboard!. Institute of Healthcare Improvement Open School, 2014. – Indicator summary Indicator summary QUM domain No. Indicator addressed by Page indicator Antithrombotic therapy Percentage of hospitalised patients that are assessed for risk 1.1 Judicious selection 24 of venous thromboembolism Percentage of hospitalised adult patients that receive venous Judicious selection 1.2 26 thromboembolism prophylaxis appropriate to their level of risk Appropriate choice Percentage of patients prescribed enoxaparin whose dosing schedule 1.3 Safe and effective use 30 is appropriate Percentage of patients prescribed hospital initiated warfarin whose loading 1.4 doses are consistent with a drug and therapeutics committee Safe and effective use 32 approved protocol Percentage of patients with an INR above 4 whose dosage has been 1.5 Safe and effective use 34 adjusted or reviewed prior to the next warfarin dose Percentage of patients with atrial fibrillation that are discharged 1.6 Judicious selection 36 on oral anticoagulants Antibiotic therapy Percentage of patients undergoing specified surgical procedures that Appropriate choice 2.1 40 receive an appropriate prophylactic antibiotic regimen Safe and effective use Percentage of prescriptions for restricted antibiotics that are concordant with Appropriate choice 2.2 44 drug and therapeutics committee approved criteria Safe and effective use Percentage of patients in whom doses of empirical aminoglycoside therapy are 2.3 Safe and effective use 48 continued beyond 48 hours Percentage of patients with community acquired pneumonia that are 2.4 Judicious selection 52 assessed using an appropriate validated objective measure
40. Thor J, Lundberg J, Ask J, et al. Application of statistical process control in healthcare improvement: systematic review. Qual Saf Health Care 2007; 16(5): 387-399. 41. Ganley H. Demonstration of analysis and reporting for the NSW Therapeutic Advisory Group. Bounty Brokers Pty Ltd, 2012. 42. Lane S, Weeks A, Scholefield H, et al. Monitoring obstetricians’ performance with statistical process control charts. BJOG 2007; 114(5): 614-618. 43. R. The Science of Improvement on a Whiteboard!. Institute of Healthcare Improvement – Open School, 2014. Indicator summary Indicator summary No. Indicator QUM domain addressed by indicator Page Antithrombotic therapy 1.1 Percentage of hospitalised patients that are assessed for risk of venous thromboembolism Judicious selection 24 1.2 Percentage of hospitalised adult patients that receive venous thromboembolism prophylaxis appropriate to their level of risk Judicious selection Appropriate choice 26 1.3 Percentage of patients prescribed enoxaparin whose dosing schedule is appropriate Safe and effective use 30 1.4 Percentage of patients prescribed hospital initiated warfarin whose loading doses are consistent with a drug and therapeutics committee approved protocol Safe and effective use 32 1.5 Percentage of patients with an INR above 4 whose dosage has been adjusted or reviewed prior to the next warfarin dose Safe and effective use 34 1.6 Percentage of patients with atrial fibrillation that are discharged on oral anticoagulants Judicious selection 36 Antibiotic therapy 2.1 Percentage of patients undergoing specified surgical procedures that receive an appropriate prophylactic antibiotic regimen Appropriate choice Safe and effective use 40 2.2 Percentage of prescriptions for restricted antibiotics that are concordant with drug and therapeutics committee approved criteria Appropriate choice Safe and effective use 44 2.3 Percentage of patients in whom doses of empirical aminoglycoside therapy are continued beyond 48 hours Safe and effective use 48 2.4 Percentage of patients with community acquired pneumonia that are assessed using an appropriate validated objective measure Judicious selection 52
SAQ127_National_QUM_Indicators_V14.docx